Stock Ratings / Health Care / PTN / options

CMMB (38) INM (47) ENSC (35) MBRX (43) ⌘ Pro Terminal →

Palatin Technologies Inc. (PTN) Options Positioning, Max Pain & Unusual Sweeps

Q: What is PTN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PTN.

$4.93 -3.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Palatin Technologies Inc. (PTN) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $8.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTN)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PTN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PTN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PTN)

✓Walkthrough of PTN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PTN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.61%🛡️ HOLDING TREND SUPPORT

2026-10-30O $4.93H $5.11L $4.90C $4.93VOL 16.0K

RES: $10.37SUP: $4.28SMA50: $9.15SMA200: $14.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PTN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PTN Butterfly Map → + Track PTN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PTN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PTN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PTN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTN)

Health Care Rank #730 of 1016 ⚔️ CMMB vs PTN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PTN vs. CMMB, INM, ENSC, MBRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Palatin Technologies Inc. (PTN) ranks #730 by composite RQD confidence (38/100, grade D-) and #906 by equity capitalization ($8.8M). Within this direct 5-issuer industry benchmark cohort, PTN leads on earnings valuation at N/A trailing P/E, while PTN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PTN at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PTN ACTIVE Palatin Technologies Inc.	D-	38/100	—	—	-35.0%	-3.33%	$8.8M	Benchmark Subject
CMMB Chemomab Therapeutics Ltd.	D-	38/100	—	—	-35.0%	-0.91%	$8.8M	/cmmb-vs-ptn →
INM InMed Pharmaceuticals Inc.	D	47/100	—	34.5%	-35.0%	+1.61%	$8.9M	/inm-vs-ptn →
ENSC Ensysce Biosciences Inc.	D-	35/100	—	—	-35.0%	-3.16%	$8.5M	/ensc-vs-ptn →
MBRX Moleculin Biotech Inc.	D-	43/100	—	—	-35.0%	-0.29%	$9.2M	/mbrx-vs-ptn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000911216

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Palatin Technologies Inc. (PTN) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $4.5M , and -100.0% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$21.3M, and free cash flow of -$21.3M (+32.4% YoY). On the balance sheet, PTN closed FY2025 with $17.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$17.3M	-$21.3M	-$21.3M	$17.9M	—
FY2024 (FY)	2024-06-30	$4.5M	$29.7M	-$31.5M	-$31.5M	$4.3M	—
FY2023 (FY)	2023-06-30	$4.9M	$36.2M	-$29.3M	-$29.3M	—	—

3. PTN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PTN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Palatin Technologies Inc. (NASDAQ: PTN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.93 (-3.33% 1D, market cap $8.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PTN ranks #730 in composite RQD confidence.

How does PTN compare to CMMB and INM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMMB (Chemomab Therapeutics Ltd.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and INM (InMed Pharmaceuticals Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M). Among the 5-stock peer group, PTN leads on earnings multiple (N/A) while PTN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PTN?

Per PTN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000911216), Palatin Technologies Inc. generated $0 in revenue (-100.0% YoY), -$17.3M in net income, and -$21.3M in free cash flow against $17.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PTN trading relative to its 50-day, 200-day, and 52-week technical levels?

PTN last traded at $4.93 (-3.33% on volume of 12,223 shares), positioning the stock -46.12% below its 50-day simple moving average ($9.15) and -64.89% below its 200-day simple moving average ($14.04). Across its 52-week range of $4.51 to $31.00, PTN sits at the 1.6% percentile with a 14-day RSI of 25.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.31 to $5.55).

PTN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PTN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PTN.

Direct Sub-Reports: PTN RQD Cockpit PTN 12M Forecast PTN Earnings & Move PTN Dividends & DRIP PTN Insiders & 13F PTN Whale Options PTN Profit Sankey PTN News & Why